Stock KDEV KAROLINSKA DEVELOPMENT AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Karolinska Development AB

Equities

KDEV

SE0002190926

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm
Other stock markets
 11:21:17 2024-04-26 am EDT 		5-day change 1st Jan Change
1.57 SEK +3.43% Intraday chart for Karolinska Development AB +3.43% -7.54%
Apr. 16 Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election CI
Feb. 16 Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Business Summary

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Number of employees: 8

Sales per Business

SEK in Million2022Weight2023Weight Delta
Investment and Related Activities
100.0 %
2 100.0 % 2 100.0 % -12.43%

Sales per region

SEK in Million2022Weight2023Weight Delta
Sweden
100.0 %
2 100.0 % 2 100.0 % -12.43%

Managers

Managers TitleAgeSince
Viktor Drvota CEO
 Chief Executive Officer 59 15-12-06
Hans Christopher Toll DFI
 Director of Finance/CFO 56 22-09-30
John Öhd CTO
 Chief Tech/Sci/R&D Officer 53 20-05-31
Per Gunnar Ernst Aniansson CIO
 Chief Investment Officer 58 21-02-28
Linda Spahiu PRN
 Corporate Officer/Principal 39 -
Johan Dighed LAW
 General Counsel 51 20-04-30
Elisabet Gimbringer PRN
 Corporate Officer/Principal 59 15-10-31
Eva Montgomerie AUD
 Comptroller/Controller/Auditor 66 06-12-31
Thomas Andersson PRN
 Corporate Officer/Principal 72 -

Members of the board

Members of the board TitleAgeSince
Björn Cochlovius CHM
 Chairman 56 19-12-31
Viktor Drvota CEO
 Chief Executive Officer 59 15-12-06
Anna Lefevre Skjöldebrand BRD
 Director/Board Member 55 21-02-18
Benjamin Toogood BRD
 Director/Board Member 48 21-02-18
Theresa Tse BRD
 Director/Board Member 32 17-11-27
Philip Duong BRD
 Director/Board Member 34 22-01-11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 2,555,261 0 0 35.96 %
Stock B 1 267,522,333 97,108,178 ( 36.30 %) 244,285 ( 0.0913 %)

Shareholders

NameEquities%Valuation
Swedbank Robur Fonder AB
3.271 %
8,750,000 3.271 % 1 M kr
FCG Fonder AB
0.6129 %
1,639,604 0.6129 % 237 365 kr
Storebrand Asset Management AS
0.0933 %
249,486 0.0933 % 36 118 kr
Holberg Fondsforvaltning AS
0.0295 %
78,822 0.0295 % 11 411 kr
Nordea Investment Management AB (Norway)
0.0206 %
55,223 0.0206 % 7 995 kr
Equinor Asset Management ASA
0.0203 %
54,300 0.0203 % 7 861 kr
Skandia Fonder AB
0.0164 %
43,902 0.0164 % 6 356 kr
Absalon Capital Fondsmaeglerselskab A/S
0.008443 %
22,586 0.008443 % 3 270 kr
Case Kapitalförvaltning AB
0.006990 %
18,700 0.006990 % 2 707 kr

Holdings

NameEquities%Valuation
OSSDSIGN AB
9.83%
 9,596,662 9.83% 9,064,815 $

Company contact information

Karolinska Development AB

Tomtebodavägen 23 A

171 65, Solna

+46 8 52 48 60 70

http://www.karolinskadevelopment.com
address Karolinska Development AB(KDEV)

Group companies

NameCategory and Sector
KDev Investments AB
Logo KDev Investments AB

KDev Investments AB

BiotechnologyHealth Technology

KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden.

Biotechnology

Sector

Healthcare
Healthcare Services
Healthcare Equipment & Supplies
Medical Equipment, Supplies & Distribution
Other Medical Equipment, Supplies & Distribution

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
KAROLINSKA DEVELOPMENT AB Stock Karolinska Development AB
-7.54% 37.56M
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.37% 185B
MEDTRONIC PLC Stock Medtronic plc
-3.58% 105B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.89% 66.59B
DEXCOM, INC. Stock DexCom, Inc.
+2.70% 54.66B
CENCORA, INC. Stock Cencora, Inc.
+16.86% 47.78B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 41.26B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.64% 26.95B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.55% 26.37B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.8B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. KDEV Stock
  4. Company Karolinska Development AB